IV Oxycodone Dosing for Breakthrough Pain

Calculation Method

The National Comprehensive Cancer Network recommends calculating the total daily oral oxycodone dose and converting it to an IV equivalent using a 2:1 ratio, with a total daily oral oxycodone dose of 60mg being equivalent to 30mg IV oxycodone per day 1, 2, 3
The oral to IV conversion ratio for oxycodone is approximately 2:1, similar to morphine's 2-3:1 ratio, according to the Annals of Oncology 4
The breakthrough dose calculation is 10-20% of the 24-hour total dose, which for a patient taking 60mg oral oxycodone per day would be 3-6mg IV per dose, as recommended by the National Comprehensive Cancer Network 5, 6

The National Comprehensive Cancer Network recommends administering 3-5mg IV oxycodone for initial breakthrough dosing, with reassessment at 15 minutes using a numerical pain scale 5, 6, 8
If pain score remains unchanged or increases, an additional 50-100% of the previous dose (1.5-5mg) should be given, while a decrease in pain score to 4-6 warrants repeating the same dose, and a decrease to 0-3 warrants holding and reassessing, as recommended by the National Comprehensive Cancer Network 8
The National Comprehensive Cancer Network also recommends increasing the scheduled oral oxycodone dose by 10-20% if a patient requires repeated breakthrough doses over 24 hours, and calculating a new breakthrough dose based on the updated 24-hour total 5, 6

The National Comprehensive Cancer Network recommends considering IV morphine as an alternative to IV oxycodone, with a conversion ratio of 60mg oral oxycodone to 10-15mg IV morphine per day, and a breakthrough dose of 1-2mg IV morphine every 15-30 minutes 1, 2, 3, 7
The National Comprehensive Cancer Network also recommends considering IV hydromorphone as an alternative, with a conversion ratio of 60mg oral oxycodone to 3mg IV hydromorphone per day, and a breakthrough dose of 0.3-0.6mg IV hydromorphone every 15-30 minutes 1, 2, 3, 9

The National Comprehensive Cancer Network recommends assessing for respiratory depression, especially during initial titration, and monitoring for sedation, which is common during dose adjustments 8, 10
Patients on chronic opioids are considered opioid-tolerant and can safely receive these doses, as stated by the National Comprehensive Cancer Network 5, 8

The National Comprehensive Cancer Network recommends reducing calculated doses by 25-50% when rotating opioids to account for incomplete cross-tolerance, and avoiding the use of fixed equianalgesic ratios rigidly 1, 2
The National Comprehensive Cancer Network also recommends avoiding underdosing breakthrough pain, using inadequate rescue doses (less than 10% of daily total), and delaying reassessment, as this can lead to poor pain control 5, 6, 8